Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Synlogic
|
| gptkbp:acquisitionYear |
2017
|
| gptkbp:focusesOn |
microRNA-based therapeutics
|
| gptkbp:foundedIn |
2007
|
| gptkbp:headquartersLocation |
gptkb:Austin,_Texas,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mirna Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:MRX34Indication |
gptkb:cancer
|
| gptkbp:MRX34Is |
microRNA mimic
|
| gptkbp:MRX34TrialStatus |
clinical trial halted in 2016
|
| gptkbp:notableProduct |
MRX34
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockSymbol |
MIRN
|
| gptkbp:website |
http://www.mirnarx.com/
|
| gptkbp:bfsParent |
gptkb:Clay_Siegall
|
| gptkbp:bfsLayer |
6
|